TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ).
CARsgen Therapeutics Holdings Ltd. has established a Nomination and Corporate Governance Committee as part of its commitment to strong corporate governance practices. This move is expected to enhance the company’s governance structure and ensure compliance with the Corporate Governance Code, potentially strengthening its market position and investor confidence.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. operates in the biotechnology industry, focusing on the development of innovative CAR-T cell therapies for the treatment of cancer. The company is committed to advancing its pipeline of products to address unmet medical needs in oncology.
Average Trading Volume: 2,897,919
Technical Sentiment Signal: Hold
Current Market Cap: HK$12.38B
See more data about 2171 stock on TipRanks’ Stock Analysis page.